Revenue YoY
+39.04%
Operating Income YoY
+19.43%
Net Income YoY
+18.90%
Net Margin Δ
+13447 bps
Net income bridge for Tango Therapeutics (TNGX) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $25.03M+18.90%
Profit bridge breakdown for Tango Therapeutics (TNGX) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | −$132.26M | — |
| Revenue | $16.00M | +63.9% |
| Cost of Revenue | −$1.57M | -6.3% |
| Operating Expenses | $13.91M | +55.6% |
| Other Income / Expense | −$3.54M | -14.1% |
| Income Tax | $231.00K | +0.9% |
| Net Loss | −$107.23M | — |
- Prior Net Income−$132.26M
- Revenue$16.00M
- Cost of Revenue−$1.57M
- Operating Expenses$13.91M
- Other Income / Expense−$3.54M
- Income Tax$231.00K
- Net Loss−$107.23M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement